Euro-Lupus低剂量环磷酰胺方案不影响SLE患者卵巢储备
研究纳入155例绝经前SLE患者,采用ELISA检测血清抗苗勒管激素(AMH)评估卵巢储备。Euro-Lupus低剂量IV CYC组AMH中位数1.46 ng/ml与未用CYC组1.85 ng/ml无差异,而>6 gm IV CYC组AMH中位数0.83 ng/ml显著低于未用组(P=0.047)。配对样本显示Euro-Lupus方案治疗前后AMH无显著变化(P=0.43)。
要点
- Euro-Lupus低剂量IV CYC累积3 gm不影响SLE患者血清AMH水平。
- 高剂量IV CYC(>6 gm)与AMH显著降低相关(P=0.047)。
- 有生育需求的SLE患者可考虑Euro-Lupus方案。
核心结论
- Euro-Lupus低剂量IV CYC方案不影响SLE患者的卵巢储备,可推荐用于有生育需求的患者。
研究设计与样本
- 队列研究纳入155例绝经前SLE患者,其中30例接受Euro-Lupus方案,24例接受更高剂量IV CYC,均未用口服CYC。
- 采用酶联免疫吸附试验检测血清AMH水平,并以未用IV CYC的SLE患者计算的斜率进行年龄校正。
主要发现
- Euro-Lupus组AMH中位数1.46 ng/ml与未用CYC组1.85 ng/ml无差异。
- >6 gm IV CYC组AMH中位数0.83 ng/ml显著低于未用CYC组(P=0.047)。
- 配对样本中Euro-Lupus方案治疗前AMH中位数1.24 ng/ml,治疗后2.50 ng/ml,差异无统计学意义(P=0.43)。
临床怎么用
- 对于有生育计划的SLE患者,Euro-Lupus低剂量IV CYC方案对卵巢储备影响小,可作为治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The Euro-Lupus regimen of low-dose intravenous cyclophosphamide (IV CYC) (cumulative dose of 3 gm) was developed to reduce gonadal toxicity. To address the possibility of a marginal effect on the ovarian reserve, we measured serum titers of anti-Müllerian hormone (AMH) in patients with systemic lupus erythematosus (SLE) treated with the Euro-Lupus regimen and compared them with those measured in patients who were treated with higher doses of IV CYC or were never treated with IV CYC. METHODS: Serum AMH levels were measured by enzyme-linked immunosorbent assay in a cohort of 155 premenopausal SLE patients; 30 of these patients had been treated with the Euro-Lupus regimen, and 24 had received higher doses of IV CYC. None had received oral CYC. AMH levels were age-adjusted using a slope computed from levels measured across the group of SLE patients who had not been treated with IV CYC. Demographic and clinical data were collected. RESULTS: Serum titers of AMH measured in SLE patients treated with the Euro-Lupus IV CYC regimen (median dose 1.46 ng/ml) did not differ from those measured in patients never treated with the cytotoxic drug (median 1.85 ng/ml). As expected, patients given >6 gm of IV CYC had significantly lower serum titers of AMH (median 0.83 ng/ml) compared with those never treated with IV CYC (P = 0.047). Median serum AMH titers did not change before (1.24 ng/ml) and after (2.50 ng/ml) treatment with the Euro-Lupus IV CYC regimen in the subset of patients for whom paired samples could be tested (P = 0.43). CONCLUSION: The Euro-Lupus regimen of low-dose IV CYC does not impact the ovarian reserve of SLE patients and can therefore be proposed as treatment in patients seeking to become pregnant.
引用
- Tamirou F, Husson SN, Gruson D, et al. Brief Report: The Euro-Lupus Low-Dose Intravenous Cyclophosphamide Regimen Does Not Impact the Ovarian Reserve, as Measured by Serum Levels of Anti-Müllerian Hormone. Arthritis Rheumatol. 2017. PMID: 28235250. doi:10.1002/art.40079
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。